 | |
 Above: molecular structure of apronalBelow: 3D representation of an apronal molecule | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.007.677 |
| Chemical and physical data | |
| Formula | C9H16N2O2 |
| Molar mass | 184.239 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Apronal (brand nameSedormid), orapronalide, also known asallylisopropylacetylurea orallylisopropylacetylcarbamide, is ahypnotic/sedativedrug of theureide (acylurea) group synthesized in 1926[1] byHoffmann-La Roche. Though it is not abarbiturate, apronal is similar instructure to the barbiturates (being an open-chaincarbamide instead of having aheterocyclic ring).[2] In accordance, it is similar in action to the barbiturates, although considerably milder in comparison (formerly used as a daytime sedative at doses of 1 to 2 grams every 3 to 4 hours).[2] Upon the finding that it caused patients to developthrombocytopenic purpura, apronal was withdrawn from clinical use.[3]
Medicines with apronal are no longer used except inJapan andSouth Korea.[3][4] AustralianTherapeutic Goods Administration issued a safety alert in May 2023 which prohibits the sale, supply and use of Japanese EVE-branded products in Australia[5] due to its dangerous side effects.
